Compounds > abbott 40174
Page last updated: 2024-12-07

abbott 40174

Description

Abbott 40174: tetrahydropyridobenzopyran derived from cannabinoid nucleus; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID99040
CHEMBL ID66108
SCHEMBL ID11354855
MeSH IDM0061826

Synonyms (36)

Synonym
5h-(1)benzopyrano(4,3-c)pyridine, 1,2,3,4-tetrahydro-5,5-dimethyl-8-(1,2-dimethylheptyl)-10-hydroxy-2-(2-propynyl)-
nsc 167790
sp-1 (van)
8-(1,2-dimethylheptyl)-1,3,4,5-tetrahydro-5,5-dimethyl-2-(2-propynyl)-2h-(1)benzopyrano(4,3-c)pyridin-10-ol
abbott 40174
2h-(1)benzopyrano(4,3-c)pyridin-10-ol, 8-(1,2-dimethylheptyl)-1,3,4,5-tetrahydro-5,5-dimethyl-2-(2-propynyl)-
8-(1,2-dimethylheptyl)-5,5-dimethyl-2-prop-2-ynyl-3,4-dihydro-1h-chromeno[4,3-c]pyridin-10-ol
{2h-[1]benzopyrano[4,3-c]pyridin-10-ol, 8-(1,2-dimethylheptyl)-1,3,4,5-tetrahydro-5,5-dimethyl-2-(2-propynyl)-
8-(1,2-dimethylheptyl)-5,5-dimethyl-2-(2-propynyl)-1,3,4,5-tetrahydro-2h-chromeno[4,3-c]pyridin-10-ol
sp-1
nsc-167790
nsc167790
2h-[1]benzopyrano[4, 8-(1,2-dimethylheptyl)-1,3,4,5-tetrahydro-5,5-dimethyl-2-(2-propynyl)-
26685-57-4
sp 1 (pharmaceutical)
CHEMBL66108
5,5-dimethyl-8-(3-methyloctan-2-yl)-2-prop-2-ynyl-3,4-dihydro-1h-chromeno[4,3-c]pyridin-10-ol
AKOS001637126
5hf6ee0tc4 ,
unii-5hf6ee0tc4
a-40174
5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4,-tetrahydro-5h-[1]benzopyrano[3,4-d]pyridine
5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)1,2,3,4-tetrahydro-5h-[1]benzopyrano[3,4-d]pyridine
5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-[1]benzopyrano [3,4-d]pyridine
PNEYWTKVWJBOMD-UHFFFAOYSA-N
5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-[1]benzopyrano[3,4-d]pyridine
SCHEMBL11354855
Q4646872
sp-1 (pharmaceutical)
2h-(1)benzopyrano(4,3-c)pyridin-10-ol, 8-(1,2-dimethylheptyl)-1,3,4,5-tetrahydro-5,5-dimethyl-2-(2-propyn-1-yl)-
abbott-40174
8-(1,2-dimethylheptyl)-1,3,4,5-tetrahydro-5,5-dimethyl-2-(2-propyn-1-yl)-2h-(1)benzopyrano(4,3-c)pyridin-10-ol
5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1)benzopyrano(3,4-d)pyridine
DTXSID00949501
5,5-dimethyl-8-(3-methyloctan-2-yl)-2-(prop-2-yn-1-yl)-1,3,4,5-tetrahydro-2h-[1]benzopyrano[4,3-c]pyridin-10-ol
5,5-dimethyl-8-(3-methyloctan-2-yl)-2-(prop-2-yn-1-yl)-2,3,4,5-tetrahydro-1h-chromeno[4,3-c]pyridin-10-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID1149205Antidiarrheal activity in Charles River rat assessed as inhibition of castor oil-induced diarrhea by measuring protected animals at 1 mg/kg, po administered 1 hr prior to castor oil challenge measured after 1 hr relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149105Analgesic activity in po dosed Sprague-Dawley rat after 15 to 90 mins by tail flick test1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150019Antipsychotic activity in Long-Evens rat assessed as reduction in methamphetamine-induced hyperactivity at 5 mg/kg, po1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1150011Antianxiety activity in albino BALB/cJ mouse assessed as decrease in foot shock-induced fighting behavior at 5 mg/kg, po by tranquilizer activity test1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1149183Antisecretory activity in Sprague-Dawley rat assessed as decrease in acid output at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150008Antidepressant activity in mouse assessed as potentiation of (+/-)Dopa-induced motor responses at 5 mg/kg, po challenged with Dopa after 4 hrs compound treatment1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID193396Percentage decrease in systolic blood pressure after 4 hr at 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193398Percentage decrease in systolic blood pressure after 4 hr at 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149168Hypnotic activity in cat assessed as increase in non-REM sleep time at 0.025 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID140544The compound was tested for activity to decrease fighting in mouse at a dose of 10 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149140Antidepressant activity in po dosed mouse assessed as potentiation of DOPA-induced effect administered 4 hrs prior to DOPA challenge1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149219Antiulcer activity in albino Sprague-Dawley rat stress ulcer model assessed as prevention of stress-induced gastric lesions by measuring ulcer index score at 40 mg/kg, po administered 30 mins prior to stress measured after 4 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149117Antianxiety activity in albino BALB/cJ mouse assessed as reduction in footshock-induced fighting behavior at 1 mg/kg, po after 30 to 90 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150017Antianxiety activity in po dosed beagle-like dog assessed as minimum dose required to produce moderate ataxia1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1149158Hypnotic activity in cat assessed as increase in total sleep time at 0.5 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150009Analgesic activity in po dosed Sprague-Dawley rat by tail flick assay1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1132947Toxicity in ip dosed Wistar rat assessed as tachycardia1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues.
AID1149166Hypnotic activity in cat assessed as increase in non-REM sleep time at 0.5 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149222Antiulcer activity in albino Sprague-Dawley rat shay ulcer model assessed as ulcer index scores at 40 mg/kg administered intraduodenally post pyloric ligation measured after 18.5 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193546The compound was tested for methamphetamine antagonism in rat at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149145Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 10 mg/kg, po after 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149218Acute toxicity in po dosed mouse1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID180354The compound was tested for analgesic activity using (RTF) tail-flick test in rat1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149146Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 3 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150022Sedative-hypnotic activity in cat assessed as change in total sleep time at 0.1 mg/kg, po after 12 hrs1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1149133Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 10 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1132949Analgesic activity in po dosed mouse by anti-writhing test1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues.
AID193547The compound was tested for methamphetamine antagonism in rat at a dose of 80 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149132Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 5 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193392Percentage decrease in systolic blood pressure after 24 hr at 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149220Antiulcer activity in albino Sprague-Dawley rat reserpine ulcer model assessed as prevention of reserpine-induced gastric lesions by measuring ulcer index scores at 50 mg/kg, po administered 30 mins prior to reserpine challenge measured after 6 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID195164The compound was tested for hyperexcitability in rat at a dose of 10 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149169Hypnotic activity in cat assessed as increase in non-REM sleep time at 0.1 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193550The compound was tested for serotonin antagonism in rat at a dose of 20 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID193536The compound was tested for decreasing motor activity in rat at a dose of 10 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149215Antiulcer activity in albino Sprague-Dawley rat shay ulcer model assessed as ulcer index scores at 20 mg/kg administered intraduodenally post pyloric ligation measured after 18.5 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149131Antianxiety activity in po dosed dog assessed as ataxia administered as single dose measured up to 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149223Antiulcer activity in albino Sprague-Dawley rat shay ulcer model assessed as ulcer index scores at 50 mg/kg administered intraduodenally post pyloric ligation measured after 18.5 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID140546The compound was tested for activity to decrease fighting in mouse at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149104Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 1 mg/kg, po after 2 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149161Hypnotic activity in cat assessed as increase in total sleep time at 0.1 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149144Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 10 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149213Antiulcer activity in albino Sprague-Dawley rat stress ulcer model assessed as prevention of stress-induced gastric lesions by measuring ulcer index score at 10 mg/kg, po administered 30 mins prior to stress measured after 4 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149120Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 10 mg/kg, po after 2 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193391Percentage decrease in systolic blood pressure after 24 hr at 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149195Antisecretory activity in Sprague-Dawley rat assessed as decrease in pepsin output at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149214Antiulcer activity in albino Sprague-Dawley rat reserpine ulcer model assessed as prevention of reserpine-induced gastric lesions by measuring ulcer index scores at 10 mg/kg, po administered 30 mins prior to reserpine challenge measured after 6 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149178Antisecretory activity in Sprague-Dawley rat assessed as decrease in acidity at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150010Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1149147Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 3 mg/kg, po after 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149228Antidiarrheal activity in Charles River rat assessed as inhibition of castor oil-induced diarrhea by measuring protected animals at 0.25 mg/kg, po administered 1 hr prior to castor oil challenge measured after 1 hr relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150015Antianxiety activity in Long-Evens rat assessed as decrease in motor activity at 10 mg/kg, po by tranquilizer activity test1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1149115Antianxiety activity in albino BALB/cJ mouse assessed as reduction in footshock-induced fighting behavior at 10 mg/kg, po after 30 to 90 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193545The compound was tested for methamphetamine antagonism in rat at a dose of 20 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149172Antisecretory activity in Sprague-Dawley rat assessed as decrease in volume at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193552The compound was tested for serotonin antagonism in rat at a dose of 80 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149123Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 0.5 mg/kg, po after 2 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149156Hypnotic activity in cat assessed as increase in total sleep time at 1 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149103Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing administered 30 mins prior to acetic acid challenge measured after 5 mins for 20 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID132466The compound was tested for analgesic activity using writhing (W) test in mouse1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1132948Analgesic activity in po dosed mouse by hot plate test1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues.
AID1149160Hypnotic activity in cat assessed as decrease in total sleep time at 0.025 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149201Antidiarrheal activity in Charles River rat assessed as inhibition of castor oil-induced diarrhea by measuring protected animals at 0.5 mg/kg, po administered 1 hr prior to castor oil challenge measured after 1 hr relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149170Hypnotic activity in cat assessed as increase in non-REM sleep time at 0.25 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID195166The compound was tested for hyperexcitability in rat at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149162Hypnotic activity in cat assessed as increase in total sleep time at 0.25 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193551The compound was tested for serotonin antagonism in rat at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		1.9510organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		1.95101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diphenoxylate
Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.		1.9510ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		3.0550benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6h-dibenzo(b,d)pyran-1-ol
3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran-1-ol: synthetic surrogate of tetrahydrocannabinol; structure		2.3620
dimethyl-heptyl tetrahydrocannabinol
dimethyl-heptyl tetrahydrocannabinol: structure given in first source		1.9510
abbott 41988
Abbott 41988: tetrahydropyridobenzopyran derived from cannabinoid nucleus; structure		2.8740
diphenoxylate hydrochloride
diphenoxylate hydrochloride : The hydrochloride salt of diphenoxylate.		1.9510hydrochlorideantidiarrhoeal drug
morphine sulfate
[no description available]		1.9510alkaloid sulfate salt
ConditionIndicatedRelationship StrengthStudiesTrials
Ataxia
Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.		01.9510
Gastric Ulcer
[description not available]		01.9510
Aggression
Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.		02.3620
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		01.9510
Blood Pressure, High
[description not available]		01.9610
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		01.9610
chemdatabank.com